Sagimet Biosciences Inc. Series A Common Stock (SGMT) — Cash Flow-to-Debt Ratio
Sagimet Biosciences Inc. Series A Common Stock (SGMT) has a Cash Flow-to-Debt Ratio of -1.63x as of March 2026, meaning its operating cash flow of $-8.61 Million could theoretically repay -2% of its total liabilities ($5.30 Million) in one year. See working capital position of Sagimet Biosciences Inc. Series A Common to evaluate short-term liquidity relative to the company's equity base.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Sagimet Biosciences Inc. Series A Common Stock Cash Flow-to-Debt Ratio (2019–2025)
Historical debt coverage capacity for Sagimet Biosciences Inc. Series A Common Stock across 7 annual periods. Also explore SGMT net asset momentum to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Sagimet Biosciences Inc. Series A Common Stock (2019–2025)
Year-by-year debt coverage analysis for Sagimet Biosciences Inc. Series A Common Stock. For market capitalisation and broader financial context, see market value of Sagimet Biosciences Inc. Series A Common.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -8.95x | $-45.65 Million | $5.10 Million | ▲ +6.1% |
| 2024 | -9.53x | $-42.44 Million | $4.45 Million | ▼ -126.7% |
| 2023 | -4.20x | $-23.77 Million | $5.65 Million | ▼ -3675.7% |
| 2022 | -0.11x | $-24.49 Million | $219.98 Million | ▼ -11.4% |
| 2021 | -0.10x | $-21.71 Million | $217.29 Million | ▼ -96.5% |
| 2020 | -0.05x | $-10.42 Million | $204.87 Million | ▲ +34.2% |
| 2019 | -0.08x | $-10.55 Million | $136.47 Million | — |